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Polycaprolactone fumarate (PCLF) is a biocompatible and biodegradable polyester which has been 
evaluated for tissue engineering. Hydrophobic PCLF nanoparticles (NPs) may be uptaken by reticule 
endotelial system rich organs and useful for treatment of related tumors. NPs of three PCLFs were 
produced through nanoprecipitation method. Crosslinked (CR) NPs were prepared using Benzyl 
peroxide (BPO) and N-vinyl pyrrolidone (NVP) under heating. Doxorubicin HCl (Dox) loaded NPs of 
PCLF530, 1250 and 2000 showed size of 149, 238 and 274 nm, respectively and zeta potential of about -
40 mV, while their drug loadings (DL%) were 2.1, 6.0 and 6.8%, respectively. Dox was released from the 
NPs in 2 to 4 days in phosphate buffer saline, pH 7.4 at 37°C. Crosslinking of NPs could be completed at 
BPO/PCLF of 0.01 and NVP/PCLF of 0.1 at 40°C with no change in NP size. PCLF530 NPs possessed a 
higher CR% than two other NPs. The CR% was reduced in formulations without NVP and with 
NVP/PCLF of 0.8. Electron microscopic images revealed spherical (CR and not CR) NPs and core-shell 
structure. PCLF1250 NPs showed both more DL% and smaller size in relation to NPs of PCLF530 and 
2000, respectively with a prolonged drug release profile and can be useful as a passive targeted drug 
delivery system. PCLF NPs could be CR (64.3%) through chemical crosslinking and consequently 
higher DL% (11.6%), longer drug release (6 days) and smaller size (188 nm) than not CR NPs. 
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INTRODUCTION 
 
Polymeric NPs are promising vehicles for drug delivery. 
Of their important capabilities is their easier manipulation 
to prepare carriers with the objective of delivering the 
drugs to the specific target (Yang et al., 2009; Kim et al., 
2000). Moreover, NPs can prolong blood circulation time 
of drugs and control the release rates of drugs in the 
tissues (Matsumura and Maeda, 1986). Poly 
(caprolactone) (PCL) is a hydrophobic biocompatible and  
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biodegradable polyester which has been used for bio-
resorbable sutures and scaffolds (Park et al., 2007) and 
for particulate drug delivery systems (Kim et al., 2000; 
Zhou et al., 2003). Its copolymer, poly (-caprolactone)–
poly (ethylene glycol) copolymers has been synthesized 
and evaluated as a drug delivery system (Huatan et al., 
1995). Fumaric acid has been used to synthesize 
polyesters suitable for crosslinking through fumarate 
double bonds like synthesized oligo (poly ethylene glycol-
fumarate) and preparation of networks by photo-
crosslinking of that (Dirk et al., 2005). Wang et al. (2006) 
have synthesized three molecular weight (Mw) of poly 
(caprolactone fumarate) (PCLF) from three Mw of PCLdiols 
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Figure 1. Schematic structure of PCLF. 
 
 
 
(nominal Mw of 530, 1250 and 2000 g/mol) as precursors  
and  used  PCLF  network  for nerve regeneration (Wang 
et al., 2006, 2009). PCLF networks can be prepared 
through photo initiated crosslinking or thermal initiated 
crosslinking (chemical crosslinking) (Wang et al., 2006, 
2009). Wang et al. (2008) have crosslinked (CR) the 
PCLFs by [bis(trimethyl benzoyl) phosphine oxide] 
(BAPO) (initiator) in methylene chloride (MC) under UV 
light which diminished the use of crosslinker. Dirk et al. 
(2005) have CR the PCLdiols oligomers by fumaric acid 
monoethyl ester in the presence of N,N-dicyclohexyl 
Carbodiimide and 4-dimethylamino pyridine at room 
temperature, and obtained networks with CR% of 68 to 
86% for tissue engineering. 
Fumarate not only makes the PCLF self-crosslinkable 
(crosslinking without incorporation of any crosslinker), but 
also enhances biodegradability of PCLF (Wang et al., 
2008, 2009). PCLF nanoparticles (NPs) seems to 
encapsulate hydrophilic drugs better than simple PCL 
NPs, because of its polar fumarate segments. Such 
characteristic can be useful for adjusting drug loading 
(DL) and drug release behavior of PCLF NPs. Besides, 
hydrophobic PCLF NPs without a stealth shell are 
assumed to be uptaken by reticuloendothelial system 
(RES) reach organs in the body (Sou et al., 2008; Paliwal 
et al., 2009) and therefore be investigated as a passive 
targeted drug delivery system for treatment of lymphoma 
in our future work. According to available literature, 
preparation of PCLF NPs has not been reported until our 
work.  
In our previous work (Shokri et al., 2011), the three Mw 
of PCLFs were synthesized (Wang et al., 2006) and 
identified and characterized by nuclear magnetic 
resonance (1H-NMR) spectra, fourier transform infrared 
(FTIR) spectra, differential scanning calorimetry (DSC) 
and gel permeation chromatography (GPC). Degradation 
behavior of powdered PCLF in different media was 
determined during one month. Nanoprecipitation method 
was compared with microemulsion polymerization 
method and was preferred for preparation of PCLF NPs 
and several parameters affecting the NP preparation 
were investigated. The stability of PCLF NPs as an 
aqueous suspension was shown to be more than two 
weeks. In this study, doxorubicin HCl (Dox) was loaded 
into the NPs of three different PCLFs and the release 
profiles were obtained following by characterization and 
comparison of these NPs. Furthermore, CR PCLF NPs 
were prepared via a chemical crosslinking method 
(because of the sensitivity of Dox to the light). The impact  
 
 
 
 
of several factors on CR% and the effect of crosslinking   
on characteristics of the NPs were investigated beside 
the comparison of the CR NPs with not CR NPs. 
 
 
MATERIALS AND METHODS 
 
Fumaryl chloride, PCLdiols (nominal number-average molecular 
weight, Mn of 530, 1250 and 2000 g mol-1), Doxorubicin HCl (Dox),  
Poly Vinyl Alcohol (PVA), N-Vinyl Pyrrolidone (NVP), Benzoyl 
Peroxide (BPO) and Dimethyl Toloidine (DMT) all were purchased 
from sigma-aldrich Co., Pottasium Carbonate (K2CO3), 
Dichloromethane or Methylene Chloride (MC), Acetone, 
Tetrahydrofuran (THF) and other chemicals were purchased from 
Merck, Germany and all were of synthesis grade. 
 
 
Synthesis of PCLF 
 
Synthesis and purification of PCLF was performed according to 
Wang et al. (2006). Briefly, three PCLdiols with nominal Mw of 530, 
1250 and 2000 were employed to be sterified with fumaryl chloride 
in the presence of K2CO3 (proton scavenger), resulting in PCLF 
copolyesters (with different Mw of about 6000, 9000 and 11000, 
respectively (Table 1) which were named after their precursors as 
PCLF530, PCLF1250 and PCLF2000. Figure 1 shows the 
schematic structure of the PCLF. CR PCLF was obtained by adding 
a solution of BPO, DMT and NVP in MC (or in same NVP where 
MC was not used) to the PCLF and then placing of the mixture 
under 60°C for 15 to 50 min (Wang et al., 2009). 
 
 
Preparation of PCLF NPs 
 
PCLF NPs were prepared through nanoprecipitation method as 
reported in our previous paper (Sou et al., 2008; Peracchia at al., 
1999). Briefly 2 ml of solution of PCLF in acetone (0.6w/v%) was 
poured into 8 ml stirring solution of PVA (0.3w/v%) in deionized 
water (DW) with or without Dox (0.2w/v%). Dox loaded NPs of three 
PCLFs and not copolymerized PCL(diol)2000 were obtained and 
compared in case of their size, zeta potential, DL and drug 
entrapment efficiency (EE). Moreover, for preparation of CR NPs, a 
solution of BPO, DMT and NVP in acetone (or in the same NVP 
when acetone was not used) and a separate solution of PCLF in 
acetone were poured in stirring DW (with or without Dox) 
simultaneously and the mixture was placed under 40°C and 
vigorous stirring for 30 to120 min. The evaporated amount of DW 
was continuously replaced with fresh DW during the heating. CR 
NPs were lyophilized (Lyotrap plus freeze dryer, LTE scientific co., 
UK) and then pressed onto a crystal in a thin layer form, to obtain 
their spectra by FTIR spectroscopy using a Nicolet FT-IR Magna 
550 spectrophotometer.  
 
 
Determination of CR% 
 
Weighted CR PCLF or CR NPs (Wi: initial weight) were immersed in 
water for two days and dried by a vacuum oven. The dried samples 
were immersed in THF for two days and weighted (Wd: dried 
weight) after drying (Dirk et al., 2005). CR% was calculated as 
below: 
 
CR% = Wd/Wi ×100 
 
To calculate the heating time needed for completing the 
crosslinking, the time which the PCLF sample or NP formulation 
reached to a constant CR% was recorded in preliminary 
experiments. Each sample was tested in triplicate. 
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Table 1. Physical characteristics of PCLdiols and PCLFs. 
 
Macromer or copolymer Mn (g/mol) MW (g/mol) PDI Tm (°C) 
PCL diol 530 792 1218 1.5 - 
PCL diol 1250 2844 4010 1.2 60 
PCL diol 2000 3092 6339 2.0 63 
PCLF530 4019 6026 1.4 - 
PCLF1250 6960 9287 1.3 57 
PCLF2000 8455 11623 1.3 59 
 
Notes: Mn , number average molecular weight; MW, weight average molecular weight; PDI, 
polydispersity index; Tm , melting point. 
 
 
 
Determination of DL% and drug release profiles 
 
Prepared NP suspension was filtered and separated using 0.1 µm 
membrane filter (PC type, Whatman, UK) and the concentration of 
unloaded drug in the filtrate solution was determined by absorbance 
of Dox in 485 nm using UV-VIS spectrophotometer (Jasco V-530, 
Jasco Co., Japan). Then DL% and EE% were calculated as below: 
 
Amount of drug in NPs = Amount of drug added initially – Amount of 
drug in filtrate solution 
 
DL (%) = Amount of drug in NPs / Amount of drug-loaded NPs × 
100 
 
EE (%) = Amount of drug in NPs / Amount of drug added initially × 
100 
 
Each sample was assayed in triplicate. 
 
To determine drug release profile, 12 mg of NPs (collected over 0.1 
µm membrane filter and washed two times with DW) was dispersed 
in 10 ml phosphate buffered saline (PBS), pH 7.4 which was poured 
into a dialysis bag. The bag was immersed in 30 ml sealed PBS, pH 
7.4 and then placed in a shaker incubator (Heidolph incubator 
1000, Heidolph Co., Germany) protected from light at 37°C under 
70 rpm. 3 ml samples of the medium was taken at certain time 
intervals (every day) and 3 ml of fresh PBS was replaced every time 
for maintaining the sink condition. The concentration of Dox in the 
samples was determined by the UV absorbance at 485 nm. Each 
sample was examined in triplicate. 
 
 
Characterization of the NPs 
 
Each formulation was prepared in triplicate and the mean size ± 
standard deviation of them was reported. The effect of several 
variables of the method on NP characteristics was evaluated in 
order to adjust NP size, DL% and CR%. Every variable was 
changed while others were constant. The size, size distribution and 
zeta potential of the NPs were measured by laser light scattering 
(PCS) (Malvern Zetasizer, Nano-ZS series, Malvern co., UK). The 
shape of NPs and their size were checked by scanning electron 
microscopy (SEM, Philips XL 30 scanning microscope, Philips co., 
the Netherlands). SEM samples were prepared by dropping 200 µl 
of each NP suspension onto a standard glass surface and removing 
water under reduced pressure.  
 
 
RESULTS AND DISCUSSION 
 
Synthesis and characterization of PCLFs and CR 
PCLFs 
 
As reported before, the 1H-NMR, FTIR, GPC and DSC 
spectra data of PCLFs were in accordance with the 
reported data by Wang et al. (2006). The Mw, 
polydispersity index (PDI) and melting point (Tm) of the 
PCLdiols and PCLFs are given in Table 1. According to 
FTIR spectra shown in Figure 4, the peak of fumarate 
double bond between 1500 and 2000 cm-1, which was 
observed for PCLF1250 NPs, was disappeared for CR 
PCLF1250 NPs, indicating the consumption of double 
bonds during crosslinking process. 
Using different concentrations of NVP and BPO and 
determining the residual of them (by UV absorbance at 
230 and 235 nm respectively) after completion of cross-
linking (constant CR%), revealed a nearly zero residual 
concentration of them when the NVP/PCLF was 0.1 and 
BPO/PCLF was 0.01. Therefore these ratios were 
considered as safe concentrations of NVP and BPO. 
Table 2 shows characteristics of CR PCLF samples. 
According to this table, it is observed that cross-linking of 
PCLF samples was accomplished efficiently at ratios of 
BPO/PCLF, DMT/PCLF and NVP/PCLF of 0.01, 0.01 and 
0.2 respectively, at 60°C. The CR% of sample 4, 5 and 6 
(80 to 94%) were higher than CR% of sample 1, 2 and 3 
(66 to 80%) demonstrating that CR% of samples 
prepared by NVP and without any solvent, were more 
than CR% of samples prepared in the presence of both 
NVP and MC. Moreover, crosslinking of samples without 
MC, was completed quicker than crosslinking of samples 
with MC. Comparing CR% of samples 1 to 3, or samples 
4 to 6 in Table 2, reveals that PCLF530 could bear much 
higher CR% in a shorter heating time than two other 
PCLFs because of its more fumarate segments and 
therefore more double bonds per copolymer chain. 
 
 
Characterization of PCLF NPs 
 
According to Table 3, NPs of PCLF2000, 1250 and 530 
had sizes of 173±7, ± and ± nm, respectively 
with narrow size distribution which was previously 
reported for nanoprecipitation method (Bilati et al., 2005). 
Comparison of size of NP formulations 1, 3 and 5 (Table 
3), made of PCLF2000, 1250 and 530 respectively, 
showed that increasing the Mw of PCLF, increased the 
NP size (Bilati et al., 2005). While NP formulations 1 and 
2 were made of PCLF2000 with PCLF concentration of 
0.6 and 1 w/v%  respectively,  NP  formulations  3  and  4 
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Table 2. CR% of CR PCLF samples prepared with or without MC (n = 3). 
 
Sample PCLF Mw (0.6w/v%) BPO/PCLF DMT/PCLF NVP/PCLF Solvent 60˚C (min) CR% 
1 530 0.01 0.01 0.2 MC 15 80.3±13.4 
2 1250 0.01 0.01 0.2 MC 50 70±21.3 
3 2000 0.01 0.01 0.2 MC 50 66.3±24.4 
4 530 0.01 0.01 0.2 - 1 94.3±4.1 
5 1250 0.01 0.01 0.2 - 15 82.3±10.6 
6 2000 0.01 0.01 0.2 - 15 80±16.4 
 
Notes: MW, weight average molecular weight; BPO, Benzoyl peroxide; DMT, Dimethyl toluidine; NVP, N-vinyl 
pyrrolidone; CR%, crosslinked percent; MC, methylene chloride. 
 
 
 
Table 3. Characteristics of unloaded NPs prepared with different formulations (n = 3). For all the NP formulations the S/NS volume 
ratio was 1:4, DW and PVA22000 (0.3w/v%) were used as non-solvent and stabilizer respectively. 
 
Formulation no. Solvent  PCLF Mw and concentration (w/v%) NP Size±SD (nm) PDI Zeta potential (mV) 
1 Acetone 2000,0.6 173±7 0.1±0.0 -31±5 
2 Acetone 2000,1 216± 0.1±0.0 -28±9 
3 Acetone 1250,0.6 ± 0.1±0.0 -28±3 
4 Acetone 1250,1 ± 0.1±0.0 -32±6 
5 Acetone 530,0.6 ± 0.1±0.0 -52±4 
6 Acetone 530,1 ± 0.1±0.0 -32±3 
7 THF 2000,0.6 191±23 0.1±0.0 -28±1 
8 NVP 2000,0.6 110±3 0.1±0.0 -17±7 
 
Notes: MW, weight average molecular weight; SD, Standard deviation; PDI, polydispersity index; THF, Tetra hydro furane; NVP, N-vinyl 
pyrolidone.  
 
 
 
were made of PCLF1250 with PCLF concentration of 0.6 
and 1 w/v% respectively and NP formulations 5 and 6 
were made of PCLF530 with PCLF concentration of 0.6 
and 1 w/v% respectively, it can be concluded that 
increasing the PCLF concentration, increased the NP 
size (Lamprecht et al., 1999). Using NVP as solvent 
resulted in smaller NPs in comparison with the NPs 
prepared by acetone as solvent. In contrast, using THF 
as solvent resulted in larger NPs in comparison with the 
NPs prepared by acetone as solvent. The PDI of all 
formulations was 0.1 indicating a narrow size distribution. 
The zeta potential was negative probably due to the 
carboxylic acid groups related to fumarate terminated 
copolymer chains. The zeta potential of NPs prepared 
with acetone was more negative than NPs prepared with 
NVP or THF.  
Table 4 shows the Dox loaded NPs. As it can be seen 
from Table 4 increasing the initial concentration of Dox 
leading to an increase in NP size and DL% (formulation 
9, 10 and 11). Such increase might indicate the 
entrapment of drug molecules in the NPs (Kim and Lee, 
2001). Among the NP formulations 11, 12 and 13, NPs of 
11 and 12 made of PCLF2000 and 1250, respectively, 
had higher DL% of about 6%. Such an observation and 
considering NP formulation 14, shows by increasing 
polymer Mw, DL% and EE% was increased. Also among 
these three formulations, NPs of 12 and 13 made of 
PCLF1250 and 530 respectively, had smaller size as 
238±20 and 149±21 nm, respectively, which were 
suitable sizes as for a passive targeting system since 
most of the NPs have sizes under 200 nm. Therefore, 
although NPs of PCLF2000 (formulation 11) had the most 
EE%, NPs of PCLF1250 (formulation 12) possessed both 
desired characteristics as high DL% and small size. Such 
quite low DL% could be related to the large surface area 
of the NPs and the high water solubility of Dox 
accelerating drug loss into the water during NP 
preparation as has been reported (Zhang et al., 2007). 
Dox loaded NPs (Table 4) had more negative zeta 
potential than unloaded NPs probably because of the 
Dox molecules on the surface of the NPs (Table 3). The 
NPs were stable and did not show any change in mean 
size over one week in aqueous suspension due to the 
surface charge of the NPs which was reported previously 
(Muller, 1991). Also they were stable and recovered over 
lyophilizing.  
 
 
Characterization of CR PCLF NPs 
 
In Table 5, all NPs were made by simultaneous addition 
of a solution of 0.6w/v% PCLF in NVP or  acetone  and  a 
  
 
 
solution of BPO and DMT in NVP or acetone, into DW. 
According to Table 5, NPs of PCLF530 showed a higher 
CR% (81%, formulation 1) than CR% of NPs of 
PCLF1250 and 2000 (49 and 44.3%, formulation 2 and 3, 
respectively). Therefore not only the fact that PCLF530 
can bear a higher CR% (mentioned in previous 
paragraphs) was confirmed, but also in comparison with 
the formulations 4 to 6 in Table 4, it can be concluded 
that PCLF NPs could have a lower CR% and need a 
longer heating time than PCLF copolymer samples, 
indicating the neutralization of the free radicals of 
crosslinking reaction by water molecules existed in NP 
preparation system. Comparison of the formulations 3, 4 
and 5, demonstrated that for NPs placed under longer 
heating time (90 min, formulation 5), CR% was increased 
(66.3%) while a heating time more than 90 min did not 
lead to a more CR% (not shown in the table). Therefore 
90 min could be an optimal heating time in such reaction. 
The very low CR% of the formulation 6 (5.6%) even after 
120 min heating, shows that where NVP/PCLF was 
increased to 0.8, CR% fell down probably because of the 
diluting role of NVP. For the formulation 7 and 8, DMT 
was not used and for the formulation 8, NVP/PCLF was 
reduced to 0.1, but the CR% of them (65 and 64.3%, 
respectively) was not significantly changed in comparison 
with the CR% of NP formulation 5 (66.3%). Therefore 
presence of DMT was not necessary and a NVP/PCLF of 
0.1 was chosen as an optimal ratio. According to 
formulations 9 to 15, the absence of NVP and the 
presence of acetone, reduced CR% dramatically (6.6 to 
12%), demonstrating the significant role of NVP in such 
crosslinking reaction. Such a fact was mentioned by Dirk 
et al. (2005) as although fumaric acid has a high 
reactivity, its lower reactivity compared to acrylates, 
makes the use of comonomers like NVP, necessary. In 
case of NP formulations with increased heating time from 
30 to 60 minutes (formulation 9 and 10, respectively), 
CR% was increased from 6.6 to 12%. While heating time 
more than 60 min did not lead to a more CR% (not shown 
in the table). CR% of NPs of PCLF530, 1250 and 2000 
(formulations 10, 11 and 12, respectively) as 12, 7 and 
9%, respectively, demonstrated again that PCLF530 NPs 
could be CR more than two other PCLFs because of its 
more double bonds. In the case of formulation 13 to 15, 
the BPO/PCLF and DMT/PCLF were increased from 0.01 
to 0.04, but the CR% was not increased considerably (8 
to 10.6%). 
In Table 6, all NPs were made by simultaneous 
addition of a solution of 0.6w/v% PCLF2000 in NVP and 
a solution of BPO and DMT in NVP (except for 
formulations 1 and 4), into DW with or without Dox. Table 
6 represents size, zeta potential and DL% of CR PCLF 
NPs. Formulation 1 was not treated with crosslinking 
agents and had a size of 133 nm. Formulations 2 and 3 
were crosslinked during a heating time of 30 and 90 min 
resulting in CR% of 43 and 65.3% respectively, which 
proved again the effect of heating time on CR%. 
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Formulations 2 and 3 had sizes of 109.6 and 136 nm 
respectively. Such a change in size implies that after 30 
min of crosslinking, NP size was decreased (133 to 109 
nm) which can be attributed to a primary shrinkage of the 
polymer during crosslinking and after 90 min of 
crosslinking, NP size was increased (109.6 to 136 nm) 
probably related to a following swelling. In addition, the 
ultimate size of CR NPs (136 nm, formulation 3) did not 
differ considerably from size of not CR NPs (133 nm, 
formulation 1). Zeta potential of these three mentioned 
formulations shows that crosslinking did not affect the 
zeta potential of the CR NPs and zeta potential of not CR 
NPs (-10 mV, formulation 1) was near to zeta potential of 
CR NPs (-17 and -11 mV, formulations 2 and 3, 
respectively). The zeta potentials of Dox loaded NPs (23 
and 36 mV, formulations 4 and 5, respectively) were 
higher than unloaded NPs (-10 to -17 mV, formulations 1 
to 3, respectively) indicating that DL could increase the 
surface charge of NPs. The latter fact was mentioned in 
previous paragraph, too. Obviously these zeta potentials 
which were related to NPs prepared by NVP, were lower 
than zeta potential of NPs prepared by acetone (Tables 3 
and 4).  
In case of NP formulation 4, no crosslinking agents 
were used and Dox was used during preparation of 
formulation with a concentration of 0.1 w/v% in water 
phase. Comparison of formulations 1 with 4, as 
mentioned before, shows that DL increased the NP size 
(133 and 141 nm, formulations 1 and 4, respectively). NP 
formulation 5 was the same as formulation 4 but 
crosslinking process was performed on it. Crosslinking in 
the presence of Dox not only increased the DL% 
dramatically (4.3 and 11.6%, formulations 4 and 5, 
respectively), but also increased the NP size (141 and 
188 nm, formulations 4 and 5, respectively) while both 
facts could be due to the role of CR shell to inhibit drug 
washing out from NP matrix as was also found before 
(Dirk et al., 2005). CR% was not changed considerably in 
the presence of Dox (65.3 and 64.3%, formulations 3 and 
5, respectively). PDI of 0.1 of all these formulations 
shows that crosslinking did not alter the monodispersity 
of NPs and the NPs were still narrow distributed after 
crosslinking.  
 
 
SEM images of the NPs 
 
SEM images as shown in Figures 2, 3, and 4, 
demonstrated narrowly dispersed and spherical shaped 
NPs and confirmed the PCS results in Table 2. No 
significant difference in the morphology was observed for 
NPs of PCLF with different Mw, whoever showing 
different sizes (Figures 2A, B and C). Figure 3 which 
presents images of CR NPs of PCLF 530, 1250 and 2000 
(A, B and C, respectively), shows that CR NPs could gain 
a more spherical shape and an unexpected more mono-
dispersity in size. Figure 4 is a close image of CR NPs of
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Figure 2. SEM images of NPs of PCLF530 (A), NPs of PCLF1250 (B) and NPs of PCLF2000 (C) (NP formulation 6, 4 and 2 respectively, Table 
3).  
 
 
 
 
 
Figure 3. SEM images of CR NPs of PCLF530 (A), CR NPs of PCLF1250 (B) and CR NPs of PCLF2000 (C) (NP 
formulation 1, 2 and 3 respectively, Table 5). CR, Crosslinked. 
 
 
 
 
 
Figure 4. A close SEM image of CR NPs of PCLF1250 (D) to 
show the core/shell structure (NP formulation 2, Table 5). Notes: 
CR, Crosslinked. 
 
 
 
PCLF1250, revealing a clear core-shell structure.  
Drug release profiles 
 
The in vitro release profile of Dox from NPs in PBS, 
shown in Figure 6, for all three types of NPs (made of 
PCLF530, 1250 and 2000) demonstrate an initial burst 
release (more than 20%) during the first 6 h of the 
release experiments, due to the fast release of the drug 
distributed close to the surface of the NPs. The 
cumulative percent of Dox released was shown to reach 
a plateau after 2 days for NPs of PCLF530 and after 4 
days for NPs of PCLF1250 and 2000. Such sustained 
release could be attributed to the slow degradation of the 
PCLF in comparison with the other polyesters beside the 
high level of hydrophobicity of PCLF inhibiting the access 
of water to the polymer during the degrardation 
(Hakkarainen and Albertsson, 2002; Eldsater et al., 2000; 
Abou Zeid et al., 2004; Harrison and Jenkins, 2004; 
Jenkins and Harrison, 2006). Faster release related to 
NPs of PCLF530, could be as a result of the small size 
and large surface area of these NPs. Moreover, 
regardless to NPs of PCLF 530, the  similarity  of  NPs  of  
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Figure 5. FTIR spectra of NPs of PCLF1250 and CR NPs of 
PCLF1250. Notes: CR, Crosslinked. 
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Figure 6. Release profile of Dox from NPs of formulations 11 to 14 (Table 3), in PBS, pH 7.4 at 
37°C. Data are shown as cumulative percent of released Dox and as mean ± SD (n = 3). Notes: 
Dox, doxorubicin HCl; PBS, Phosphate buffer saline; SD, Standard deviation 
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Figure 7. Release profile of Dox from NPs of formulations 11 (Table 3) and 5 (Table 6), in PBS, pH 7.4 at 37˚C. Data 
are shown as cumulative percent of released drug and as mean ± SD (n = 3). Notes: Dox, doxorubicin HCl; PBS, 
Phosphate buffer saline; SD, Standard deviation. 
 
 
 
PCLF1250 and 2000, confirmed the reported data as Mw 
of polymer did not affect the drug release profile 
discriminately (El Malah and Nazzal, 2006). Dox release 
from not polymerized PCL NPs, was much quicker than 
the PCLF NPs and it reached to a maximum of 86.7% 
after 2 days showing relatively high SD. This could be 
because of the low Mw of the PCL(diol) 2000 macromer 
which apparently made unstable or fast desintegratable 
NPs. In Figure 7 it can be observed that the release rate 
of Dox from PCLF2000 NPs was more than Dox release 
from CR PCLF2000 NPs. PCLF2000 and CR PCLF2000 
NPs released about 25.9 and 19.9% of their drug in first 6 
h and 81.8 and 78.6% of their drug during 4 and 8 days, 
respectively. Such release profile was mainly due to the 
diffusion of the dissolved drug molecules through the 
polymeric matrix of the NPs, which was inhibited 
partiallyby CR shell in case of CR NPs. 
 
 
Conclusion 
 
PCLF copolymers with three different Mw (named 
PCLF530, PCLF1250 and PCLF2000) were synthesized 
from PCLdiols and fumaryl chloride. The PCLFs were 
used to prepare Dox loaded NPs through Nano-
precipitation method. NP size dramatically increased 
when Mw and concentration of the PCLF was increased. 
PCLF530 made smaller NPs (149 nm) than two other 
PCLFs. PCLF1250 and 2000 NPs with size of 238 and 
274 nm, had the more DL% as 6 and 6.8%, respectively. 
Based on these results of size and DL%, and also the 
PDI and zeta potential, PCLF1250 was seemed to be 
more suitable than two other PCLFs for preparation of a 
nanoparticulate drug delivery system. PCLF2000 NPs 
had the most EE% as 20.4%. The PDI of NP size were 
0.1 indicating narrowly dispersed NPs. NPs of 
PCLdiol2000 (not copolymerized macromer) showed a 
low formulation reproducibility and could load the less 
Dox than NPs of PCLFs. Besides, PCL NPs had a low 
zeta potential which could decrease their stability as 
suspension. In contrast, Dox loaded PCLF NPs 
possessed a relatively high zeta potential (about -40 mV) 
which could provide their stability against aggregation 
and etc. Increasing the initial drug concentration caused 
a significant increase in the DL% and NP size. Moreover, 
increasing the PCLF Mw or concentration significantly 
increased the NP size. 
CR PCLFs and CR NPs were prepared by BPO 
(initiator), DMT (accelerator) and NVP (comonomer) 
under the heating. FTIR spectra beside the CR%, proved 
the performance of crosslinking reaction. CR% or gel 
content was calculated by a sol extraction method to 
determine the level of crosslinking of samples. CR% was 
higher when NVP was used without any other solvent 
and PCLF530 showed a higher CR% in comparison with 
two other PCLFs. Best ratios  of  BPO/PCLF,  DMT/PCLF 
  
 
 
and NVP/PCLF were found to be 0.01, 0.01 and 0.1, 
respectively. CR% was minimized when NVP was more 
than needed. Increasing the heating time could increase 
CR% until the complete crosslinking (a constant CR%) 
and a 90 min heating was found to be enough for a 
complete crosslinking reaction. Complete crosslinking 
(without DL) did not affect NP size and PDI but increased 
the DL% to 11.6% and subsequently increased the NP 
size to 188 nm. NPs prepared by NVP as solvent instead 
of acetone, showed a lower zeta potential of -10 to -17 
mV which after DL was increased to -23 and -36 mV. 
SEM images of PCLF NPs and CR PCLF NPs 
confirming the PCS results, presented spherical narrowly 
dispersed NPs which were better shaped and with lower 
PDI in case of CR NPs than not CR NPs. A closed image 
of CR PCLF1250 NPs, revealed a core-shell structure as 
the result of crosslinking process. Dox was released from 
PCLF NPs, with a burst release of about 20% after 6 h 
and about 80% release during 2 or 4 days. Dox release 
from PCLdiol2000 NPs was much more rapid with a high 
SD. Dox release from CR PCLF2000 NPs, showed a 
slightly lower burst release after 6 h in comparison with 
Dox release from PCLF2000 NPs and also showed a 
slower release of 78.6% in 8 days. Overally, PCLF NPs 
could be prepared by nanoprecipitation method, with 
suitable size, PDI, zeta potential and DL% for a nano-
particulate drug delivery system. PCLF NPs could be CR 
successfully resulting in NPs with suitable size, increased 
DL%, improved spherical shape and a sustained drug 
release profile.  
 
 
Abbreviations: PCL, Poly caprolactone; PCLF, poly 
caprolactone fumarate; NP, nanoparticle; DW, deionized 
water; PBS, phosphate buffered saline; Dox, doxorubicin 
HCl; CR, crosslinked; PVA, polyvinyl alcohol; BPO, 
benzoyl peroxide; DMT, dimethyl toluidine; NVP, N-vinyl 
pyrrolidone; MC, methylene chloride; THF, tetra hydro 
furan; DL, drug loading; EE, drug entrapment efficiency; 
Mw, molecular weight; Tm, melting temperature; PDI, 
polydispersity index; SD, standard deviation; RES, 
reticuloendotelial system; SEM, scanning electron 
microscopy.  
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